|D003141||Communicable Diseases NIH||0.07|
|D045169||Severe Acute Respiratory Syndrome NIH||0.04|
There is one clinical trial.
Team work is highly challenged by the COVID-19 pandemic. Necessary protective equipment as FFP-mask and face shields impair communication significantly.Objective of the study is to evalaute the impact of digital enhanced telecommunication in endoscopic procedures.
Description: Adverse events arising from impaired communication by COVID-19 protection equipmentMeasure: Communication associated adverse events Time: From start to stop of endoscopic procedure
Description: Severe adverse evatent, not arising from from impaired communication by COVID-19 protection equipmentMeasure: Severe adverse events Time: From start to stop of endoscopic procedure
Description: Subjectiveley perceived level of comfort using DECT communication during endoscopic procedures rated by numeric rating scale (1-6)Measure: Subjective Comfort of DECT communication Time: From start to stop of endoscopic procedure
Description: Duration of performed endoscopic proceduresMeasure: Endoscopic time Time: From start to stop of endoscopic procedure
Data processed on January 01, 2021.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports